Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc.
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 240
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sheldon L. Koenig | President, CEO & Director | 1.28M | N/D | 1966 |
| Dr. JoAnne Micale Foody FACC, M.D. | Chief Medical Officer | 856.87k | N/D | 1965 |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 718.86k | N/D | 1972 |
| Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | N/D | N/D | 1986 |
| Mr. Glenn P. Brame | Chief Technical Operations Officer | N/D | N/D | 1958 |
| Mr. Benjamin O. Looker J.D. | General Counsel & Corporate Secretary | 550.35k | N/D | 1982 |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | N/D | N/D | N/D |
| Ms. Betty Jean Swartz | Chief Business Officer | N/D | N/D | N/D |
Descripción
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Gestión corporativa
La calificación ISS Governance QuickScore de Esperion Therapeutics, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 8; Compensación: 9.
